Kong-peng F. Lam
Pokfulam Road
Hong Kong, HCW, Hong Kong Special Administrative Region
Hong Kong, HCW, Hong Kong Special Administrative Region
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications
G3BP1 methylation by PRMT5 facilitates its recruitment of TBK1 for IRF3 activation during host response to foreign ribonucleic acids.
Journal: Frontiers in immunology
Published: May 22, 2026
Essential tips on sample size calculation and biostatistics.
Journal: Best practice & research. Clinical obstetrics & gynaecology
Published: April 06, 2026
Nur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma.
Journal: Nature communications
Published: October 01, 2025
HnRNP A1 and A2B1 enforce Ezh2 mRNA splicing to promote germinal center B cell responses.
Journal: Nature communications
Published: September 23, 2025
Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma.
Journal: Blood advances
Published: August 27, 2025
Possible Roles for Purinergic Receptor P2RX4 in Breast and Prostate Cancers.
Journal: International journal of molecular sciences
Published: August 27, 2025
Engineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma.
Journal: Blood advances
Published: August 27, 2025
B-cell activation underpins Rituximab response in focal segmental glomerulosclerosis.
Journal: Translational research : the journal of laboratory and clinical medicine
Published: June 12, 2025
Atypical memory B cells acquire Breg phenotypes in hepatocellular carcinoma.
Journal: JCI insight
Published: February 25, 2025
Gut microbiota-derived GlcNAc-MurNAc is a TLR4 agonist that protects the host gut.
Journal: Nature communications
Published: February 13, 2025
Nucleofection-based screening of chimeric antigen receptor candidates in human natural killer cells.
Nucleofection-based screening of chimeric antigen receptor candidates in human natural killer cells.
Journal: Frontiers in immunology
Published: January 09, 2025
Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment.
Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment.
Journal: Antibodies (Basel, Switzerland)
Published: October 03, 2024
Last Updated: 09/26/2026